APAC infectious disease diagnostics market growing at 13.2%

Source：Frost & Sullivan Release Date：2012-08-27 274

Medical Equipment

SINGAPORE – New analysis from Frost & Sullivan predicts growth of the Asia Pacific (APAC) infectious disease diagnostics market at 13.2 percent, to reach revenues of $3,063.2 million by 2016. The study, Asia Pacific Infectious Disease Diagnostics Market, analyzes the immunochemistry, molecular diagnostics, and microbiology market for the treatment of malaria, dengue, tuberculosis, HIV, hepatitis C, sexually transmitted infections (STIs), influenza, and pertussis.

The study reports increased priority of controlling infectious diseases as Asian countries position themselves as a popular medical tourism destination. Hence, these countries are focusing on ways to improve disease diagnostics in high risk endemic areas.

"Vector borne diseases such as dengue and malaria were prevalent only in developing and emerging economies in Asia; however, blood borne diseases like HIV and Hepatitis are an issue in most of the Asia Pacific countries," Frost & Sullivan consultant Poornima Srinivasan says. "Elimination strategies and national diagnosis policies focusing on microbiology testing and molecular testing are gaining grounds and these countries aim to be free from infectious disease by 2030."

According to the study, the ageing population and increased incidence of infectious diseases are expected to cause increase in the number of private hospitals and stand-alone laboratories. These factors drive the need for sophisticated technologies in the diagnostic testing of infectious diseases.

In most Asia Pacific countries, the market is technology and price driven. Thus, the study reports that competitive pricing and relationship with distributors are the way forward for vendors in this market.

"Most countries are expected to adapt molecular diagnostic testing for blood borne infectious disease," said Srinivasan. "It is likely that with huge research and development investments, multinational companies will continue to dominate the market after making an early entry in the molecular diagnostic segments for infectious diseases."

Entrainement Nike